One in eight cancers worldwide linked to infections, WHO agency says

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-29T21:25:32.464Z • Permanent link

The World Health Organization's International Agency for Research on Cancer (IARC) has released a groundbreaking study revealing that one in eight cancers worldwide is linked to infections. According to the report, approximately 2.3 million new cancer cases in 2024 were caused by infections, accounting for about 12% of all new cancer cases globally. Dr. Maria Van Kerkhove, a leading expert in infectious diseases at the World Health Organization, highlighted the importance of this finding, stating that "infections are a major risk factor for cancer, and addressing this issue is crucial for reducing the global burden of cancer." The IARC's research was based on a comprehensive review of existing data from over 100 countries, and the findings have significant implications for the development of cancer prevention and treatment strategies.

The study's lead author, Dr. Xiang Lin, emphasized the importance of understanding the relationship between infections and cancer. "Our research highlights the need for a more nuanced approach to cancer prevention and treatment, one that takes into account the role of infections in the development of cancer," she said. The IARC's findings are supported by data from the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI), which have also identified infections as a significant risk factor for certain types of cancer, including cervical, liver, and stomach cancer. The IARC's report is a major breakthrough in the field of cancer research and has significant implications for the development of new cancer prevention and treatment strategies.

The IARC's report is the culmination of years of research and collaboration between experts from around the world. The agency's work is supported by a network of institutions, including the World Health Organization, the CDC, and the NCI, which have all contributed to the development of the report. The IARC's findings are also supported by data from the Global Cancer Observatory, which provides a comprehensive overview of cancer incidence and mortality rates around the world. The report's release is a major milestone in the fight against cancer, and it highlights the need for continued research and collaboration between experts in the field.

The IARC's report has significant implications for the Data Sources domain, which is closely tied to the development of cancer prevention and treatment strategies. The report's findings have major implications for companies that develop cancer vaccines and treatments, as well as for research communities that are working to develop new cancer prevention and treatment strategies. The report's release is also likely to have a significant impact on markets, including the pharmaceutical and biotechnology sectors, which are heavily invested in cancer research and development.

The IARC's report also has significant implications for policy environments, particularly in low- and middle-income countries, where access to cancer diagnosis and treatment is often limited. The report's findings highlight the need for increased investment in cancer research and development, as well as in the development of cancer prevention and treatment strategies that are tailored to the needs of low- and middle-income countries. The report's release is a major call to action for policymakers and researchers, who must work together to address the global burden of cancer.

The IARC's report is also likely to have a significant impact on the development of new cancer prevention and treatment strategies. The report's findings highlight the need for a more nuanced approach to cancer prevention and treatment, one that takes into account the role of infections in the development of cancer. The report's release is a major opportunity for researchers and policymakers to work together to develop new cancer prevention and treatment strategies that are tailored to the needs of different populations and regions.